GSK plc announced on October 21, 2025, the successful Phase III trial results for tebipenem HBr, showing its effectiveness as an oral treatment for complicated urinary tract infections (cUTIs), with a 58.5% success rate compared to 60.2% for the intravenous alternative. This breakthrough could reduce hospital treatments for such infections and will be submitted for FDA approval later this year.